当前位置：
X-MOL 学术
›
Liver Cancer
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition).
Liver Cancer ( IF 11.6 ) Pub Date : 2024-01-16 , DOI: 10.1159/000535496 Xiufeng Liu 1 , Yinying Lu 2 , Weiping Zhou 3 , Tao Peng 4 , Jie Zhou 5 , Huaqiang Bi 6 , Feng Xia 6 , Xiaoping Chen 7
Liver Cancer ( IF 11.6 ) Pub Date : 2024-01-16 , DOI: 10.1159/000535496 Xiufeng Liu 1 , Yinying Lu 2 , Weiping Zhou 3 , Tao Peng 4 , Jie Zhou 5 , Huaqiang Bi 6 , Feng Xia 6 , Xiaoping Chen 7
Affiliation
Background
Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC.
Summary
To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the "Delphi" consensus formation method, and finally revised and completed the "Chinese Multidisciplinary Expert Consensus on the Immune Checkpoint Inhibitors (ICIs)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)" on the basis of the 2021 edition.
Key Messages
This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.
更新日期：2024-01-16
京公网安备 11010802027423号